These Analysts Revise Their Forecasts On UiPath Following Q2 Results

UiPath reported Q2 EPS of $0.15 (in line) and revenue of $410.26M, beating the $397.95M consensus. Despite raising FY27 sales guidance to $1.789B–$1.794B versus $1.778B expected, PATH shares fell 12.4% to $15.98. Analysts issued mixed post-earnings takes (Canaccord cut to Hold; DA Davidson kept Neutral) alongside updated price targets.

Analysis

The tape is telling you the market cares less about the raised outer-year number and more about the lack of visible near-term inflection. In enterprise software, a beat-plus-raise only works when investors believe the company is moving from “maintenance growth” to a self-funding expansion phase; here the selloff implies that confidence is still missing, so multiple compression can continue even if reported revenue is fine.

Competitive pressure likely comes less from direct feature parity and more from suite bundling. Microsoft and ServiceNow can absorb automation use cases into broader workflow purchases, which lowers PATH’s pricing power and makes incremental deal wins harder to translate into durable ARR acceleration. That dynamic is second-order bearish for smaller pure-plays across the automation/low-code stack, while beneficiaries are the platforms already inside the enterprise budget.

The key risk to the bearish read is that this may simply be a positioning flush after a crowded short-term setup, not a fundamental break. Over 1-3 months, the stock needs to prove that bookings, net retention, or pipeline conversion are reaccelerating; otherwise the market will anchor on slower growth and value the name as a low-multiple legacy software asset rather than a premium automation platform. Over 6-18 months, the thesis fails if management can turn FY27 into a credible pathway to sustained double-digit growth with expanding operating leverage.

Contrarian view: the market may be overreacting to the share move itself. If the raise reflects conservative planning rather than demand weakness, the current selloff could create a tradable dislocation, but only if the next print shows clear monetization improvement rather than just better headline revenue.

Key Decisions for Investors

• Short PATH on post-earnings strength into the $17.50-$18.50 zone over the next 1-3 weeks; target a retest of the mid-$14s, with a stop above $19.25. Best risk/reward if the gap-down fails to fill and sell-side downgrades continue.
• Pair trade: long MSFT or NOW / short PATH for 1-3 months to express enterprise automation consolidation. Thesis works if buyers prefer bundled workflow platforms over standalone automation vendors; invalidate if PATH posts a clear bookings/NRR inflection next quarter.
• If implied volatility remains elevated, use a bearish put spread in PATH (45-60 DTE) rather than outright puts; structure around current post-gap levels to limit premium outlay while keeping upside from further multiple compression.
• Set a watch item on PATH’s next disclosure for billings, remaining performance obligations, and operating margin guide. A sustained move back above $18 on improving bookings would falsify the short thesis; below $15 increases odds of another de-rating leg.
• No aggressive long until the company proves monetization acceleration. If you want exposure to automation upside, favor diversified platforms over PATH for the next 6-18 months.